JP6581604B2 - 予防的または治療的適用のためのリポソーム球状核酸による免疫調節物質の多価送達 - Google Patents
予防的または治療的適用のためのリポソーム球状核酸による免疫調節物質の多価送達 Download PDFInfo
- Publication number
- JP6581604B2 JP6581604B2 JP2016570952A JP2016570952A JP6581604B2 JP 6581604 B2 JP6581604 B2 JP 6581604B2 JP 2016570952 A JP2016570952 A JP 2016570952A JP 2016570952 A JP2016570952 A JP 2016570952A JP 6581604 B2 JP6581604 B2 JP 6581604B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- oligonucleotide
- lipid
- nanostructure
- oligonucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462007528P | 2014-06-04 | 2014-06-04 | |
| US62/007,528 | 2014-06-04 | ||
| PCT/US2015/034226 WO2015187966A1 (en) | 2014-06-04 | 2015-06-04 | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524658A JP2017524658A (ja) | 2017-08-31 |
| JP2017524658A5 JP2017524658A5 (enExample) | 2018-07-12 |
| JP6581604B2 true JP6581604B2 (ja) | 2019-09-25 |
Family
ID=53887176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570952A Active JP6581604B2 (ja) | 2014-06-04 | 2015-06-04 | 予防的または治療的適用のためのリポソーム球状核酸による免疫調節物質の多価送達 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10434064B2 (enExample) |
| EP (2) | EP3164113B1 (enExample) |
| JP (1) | JP6581604B2 (enExample) |
| KR (1) | KR102290205B1 (enExample) |
| CN (1) | CN106535876B (enExample) |
| AU (1) | AU2015269412B2 (enExample) |
| CA (1) | CA2953216C (enExample) |
| ES (1) | ES2725948T3 (enExample) |
| PL (1) | PL3164113T3 (enExample) |
| TR (1) | TR201908550T4 (enExample) |
| WO (1) | WO2015187966A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| CA2919268C (en) | 2013-07-25 | 2023-09-05 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
| WO2015126502A2 (en) | 2013-12-03 | 2015-08-27 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
| US10413565B2 (en) | 2014-04-30 | 2019-09-17 | Northwestern University | Nanostructures for modulating intercellular communication and uses thereof |
| AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| BR112017007012A2 (pt) | 2014-10-06 | 2018-03-06 | Exicure Inc | compostos anti-tnf |
| WO2016081911A2 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| US10517924B2 (en) | 2014-11-24 | 2019-12-31 | Northwestern University | High density lipoprotein nanoparticles for inflammation |
| EP3247796A4 (en) | 2015-01-14 | 2018-07-11 | Exicure, Inc. | Nucleic acid nanostructures with core motifs |
| US20180042848A1 (en) * | 2015-02-18 | 2018-02-15 | Exicure, Inc. | Immuno-regulatory lipid containing spherical nucleic acids |
| US10078092B2 (en) | 2015-03-18 | 2018-09-18 | Northwestern University | Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules |
| US20200297867A1 (en) * | 2016-02-01 | 2020-09-24 | Exicure, Inc. | Surface functionalization of liposomes and liposomal spherical nucleic acids (snas) |
| WO2017193081A1 (en) * | 2016-05-06 | 2017-11-09 | Exicure, Inc. | Spherical nucleic acid tlr9 agonists |
| CA3023451A1 (en) | 2016-05-06 | 2017-11-09 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna |
| WO2017193084A1 (en) * | 2016-05-06 | 2017-11-09 | Exicure, Inc. | Tlr9-targeted spherical nucleic acids having potent antitumor activity |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| KR20240161198A (ko) * | 2017-03-29 | 2024-11-12 | 인스티튜트 오브 베이직 메디컬 사이언시즈, 차이니즈 아카데미 오브 메디컬 사이언시즈 | 핵산 전달제 및 그의 관련 제품의 제조에 있어서의 화합물 또는 전통 중국 의약 추출물의 적용 |
| JP7252132B2 (ja) * | 2017-03-29 | 2023-04-04 | インスティテュート オブ ベーシック メディカル サイエンシズ チャイニーズ アカデミー オブ メディカル サイエンシズ | 核酸送達試薬の調製における化合物または伝統的漢方薬抽出物の応用およびその関連生成物 |
| US20200248183A1 (en) * | 2017-04-03 | 2020-08-06 | Subbarao Nallagatla | Tlr9-targeted spherical nucleic acids having potent antitumor activity |
| WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2018209270A1 (en) * | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| JP2020526558A (ja) | 2017-07-13 | 2020-08-31 | ノースウェスタン ユニバーシティ | オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法 |
| CN111601900A (zh) * | 2017-11-02 | 2020-08-28 | 詹森生物制药有限公司 | 寡核苷酸构建体及其用途 |
| US20200384104A1 (en) * | 2017-12-15 | 2020-12-10 | Northwestern University | Structure-Function Relationships in the Development of Immunotherapeutic Agents |
| US20210100905A1 (en) * | 2018-03-29 | 2021-04-08 | Institute Of Basic Medical Sciences Chinese Academy Of Medicalsciences | Application of compound or traditional chinese medicine extract in preparation of nucleic acid delivery agent, and related products |
| CA3098623A1 (en) | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| US12642850B2 (en) * | 2019-01-24 | 2026-06-02 | Massachusetts Institute Of Technology | Nucleic acid nanostructure platform for programming immune stimulation |
| US20220088059A1 (en) * | 2019-02-12 | 2022-03-24 | Exicure Operating Company | Combined spherical nucleic acid and checkpoint inhibitor for antitumor therapy |
| US12702719B2 (en) | 2019-03-06 | 2026-08-11 | Northwestern University | Hairpin-like oligonucleotide-conjugated spherical nucleic acid |
| US12319711B2 (en) | 2019-09-20 | 2025-06-03 | Northwestern University | Spherical nucleic acids with tailored and active protein coronae |
| CN110559263B (zh) * | 2019-10-10 | 2021-05-14 | 中国海洋大学 | 一种△5-胆甾硫酸基类化合物脂质体及其制备方法 |
| US12378560B2 (en) | 2019-10-29 | 2025-08-05 | Northwestern University | Sequence multiplicity within spherical nucleic acids |
| US20210220454A1 (en) * | 2020-01-22 | 2021-07-22 | Northwestern University | Design of immunostimulatory protein-core spherical nucleic acids |
| KR20230004563A (ko) * | 2020-04-10 | 2023-01-06 | 노오쓰웨스턴 유니버시티 | 강력한 암 면역치료제로서 리포좀성 구형 핵산 내 캡슐화된 산화된 종양 세포 용해물 |
| EP4304640A1 (en) * | 2021-03-12 | 2024-01-17 | Northwestern University | Antiviral vaccines using spherical nucleic acids |
| EP4547258A4 (en) * | 2022-06-28 | 2026-08-05 | Transcode Therapeutics Inc | Matrix-Directed Rig-I Agonitor Nanoparticles and Precursor Compositions and Their Uses in Cancer Therapy |
| CN118903116B (zh) * | 2023-05-08 | 2025-08-12 | 中山大学 | 溶血磷脂酸抑制剂在制备抑制prrsv复制药物中的应用 |
| WO2025089649A1 (ko) * | 2023-10-26 | 2025-05-01 | 주식회사 차백신연구소 | 양이온성 리포좀을 포함하는 핵산 전달용 조성물 및 그의 용도 |
| CN120168626A (zh) | 2023-12-15 | 2025-06-20 | 远大赛威信生命科学(南京)有限公司 | 免疫佐剂组合物及其制备方法和用途 |
Family Cites Families (486)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4489055A (en) | 1978-07-19 | 1984-12-18 | N.V. Sopar S.A. | Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
| JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
| FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
| US4605735A (en) | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
| US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
| US5008050A (en) | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
| US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
| FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
| US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
| US5258506A (en) | 1984-10-16 | 1993-11-02 | Chiron Corporation | Photolabile reagents for incorporation into oligonucleotide chains |
| US4828979A (en) | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
| FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5317098A (en) | 1986-03-17 | 1994-05-31 | Hiroaki Shizuya | Non-radioisotope tagging of fragments |
| JPS638396A (ja) | 1986-06-30 | 1988-01-14 | Wakunaga Pharmaceut Co Ltd | ポリ標識化オリゴヌクレオチド誘導体 |
| EP0260032B1 (en) | 1986-09-08 | 1994-01-26 | Ajinomoto Co., Inc. | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers |
| US5541308A (en) | 1986-11-24 | 1996-07-30 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
| US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| EP0366685B1 (en) | 1987-06-24 | 1994-10-19 | Howard Florey Institute Of Experimental Physiology And Medicine | Nucleoside derivatives |
| JP3012244B2 (ja) | 1987-09-21 | 2000-02-21 | ジェン―プローブ インコーポレイテッド | ヌクレオチドプローブ用非ヌクレオチド連結試薬 |
| US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
| US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
| JP3019994B2 (ja) | 1987-11-30 | 2000-03-15 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法 |
| EP0406309A4 (en) | 1988-03-25 | 1992-08-19 | The University Of Virginia Alumni Patents Foundation | Oligonucleotide n-alkylphosphoramidates |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
| US5262536A (en) | 1988-09-15 | 1993-11-16 | E. I. Du Pont De Nemours And Company | Reagents for the preparation of 5'-tagged oligonucleotides |
| US5194599A (en) | 1988-09-23 | 1993-03-16 | Gilead Sciences, Inc. | Hydrogen phosphonodithioate compositions |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| US5451463A (en) | 1989-08-28 | 1995-09-19 | Clontech Laboratories, Inc. | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides |
| US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
| US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
| US5721218A (en) | 1989-10-23 | 1998-02-24 | Gilead Sciences, Inc. | Oligonucleotides with inverted polarity |
| US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
| US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
| WO1991006556A1 (en) | 1989-10-24 | 1991-05-16 | Gilead Sciences, Inc. | 2' modified oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
| US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
| US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
| US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
| US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
| US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
| US5955589A (en) | 1991-12-24 | 1999-09-21 | Isis Pharmaceuticals Inc. | Gapped 2' modified oligonucleotides |
| US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
| US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
| US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| WO1991013080A1 (en) | 1990-02-20 | 1991-09-05 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
| US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
| US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
| US5688941A (en) | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
| JPH0874B2 (ja) | 1990-07-27 | 1996-01-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド |
| US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
| US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| JPH06502300A (ja) | 1990-08-03 | 1994-03-17 | サノフィ | 遺伝子発現の抑制のための化合物及び方法 |
| US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
| US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
| US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
| US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
| WO1992005186A1 (en) | 1990-09-20 | 1992-04-02 | Gilead Sciences | Modified internucleoside linkages |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| FR2677272B1 (fr) | 1991-06-05 | 1995-03-03 | Biovecteurs As | Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique. |
| US5371241A (en) | 1991-07-19 | 1994-12-06 | Pharmacia P-L Biochemicals Inc. | Fluorescein labelled phosphoramidites |
| US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
| DE59208572D1 (de) | 1991-10-17 | 1997-07-10 | Ciba Geigy Ag | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
| JP2823959B2 (ja) | 1991-10-24 | 1998-11-11 | アイシス・ファーマシューティカルス・インコーポレーテッド | 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド |
| US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
| US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
| TW393513B (en) | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
| FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
| US5814666A (en) | 1992-04-13 | 1998-09-29 | The United States As Represented By The Department Of Health And Human Services | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
| US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
| ATE143730T1 (de) | 1992-04-22 | 1996-10-15 | Ecole Polytech | Lipidmembranen fur biosensoranwendungen |
| US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
| EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
| WO1994001550A1 (en) | 1992-07-02 | 1994-01-20 | Hybridon, Inc. | Self-stabilized oligonucleotides as therapeutic agents |
| US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
| US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
| GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
| EP0691968B1 (en) | 1993-03-30 | 1997-07-16 | Sanofi | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
| HU9501974D0 (en) | 1993-03-31 | 1995-09-28 | Sterling Winthrop Inc | Oligonucleotides with amide linkages replacing phosphodiester linkages |
| DE4311944A1 (de) | 1993-04-10 | 1994-10-13 | Degussa | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
| EP1253199A1 (en) | 1993-09-02 | 2002-10-30 | Ribozyme Pharmaceuticals, Inc. | Abasic moieties containing enzymatic nucleic acids |
| US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
| US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
| US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| DK0733059T3 (da) | 1993-12-09 | 2000-10-16 | Univ Jefferson | Forbindelser og fremgangsmåder til site-rettede mutationer i eukaryote celler |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
| US5646269A (en) | 1994-04-28 | 1997-07-08 | Gilead Sciences, Inc. | Method for oligonucleotide analog synthesis |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| ES2336857T3 (es) | 1995-05-04 | 2010-04-16 | Gilead Sciences, Inc. | Complejos de ligandos de acido nucleico. |
| US5912340A (en) | 1995-10-04 | 1999-06-15 | Epoch Pharmaceuticals, Inc. | Selective binding complementary oligonucleotides |
| US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| AU3379597A (en) | 1996-06-19 | 1998-01-07 | Hybridon, Inc. | Modulation of tetraplex formation by chemical modifications of a g4-containing oligonucleotide |
| US6506564B1 (en) | 1996-07-29 | 2003-01-14 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
| US6361944B1 (en) | 1996-07-29 | 2002-03-26 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
| US20020172953A1 (en) | 1996-07-29 | 2002-11-21 | Mirkin Chad A. | Movement of biomolecule-coated nanoparticles in an electric field |
| US7098320B1 (en) | 1996-07-29 | 2006-08-29 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
| US6750016B2 (en) | 1996-07-29 | 2004-06-15 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
| US6582921B2 (en) | 1996-07-29 | 2003-06-24 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses thereof |
| WO1998004740A1 (en) | 1996-07-29 | 1998-02-05 | Nanosphere Llc | Nanoparticles having oligonucleotides attached thereto and uses therefor |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| EP0856579A1 (en) | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | An antisense oligonucleotide preparation method |
| CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| US20030104044A1 (en) | 1997-05-14 | 2003-06-05 | Semple Sean C. | Compositions for stimulating cytokine secretion and inducing an immune response |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| EP1015469B2 (en) | 1997-09-12 | 2015-11-18 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| US6271209B1 (en) | 1998-04-03 | 2001-08-07 | Valentis, Inc. | Cationic lipid formulation delivering nucleic acid to peritoneal tumors |
| US6287765B1 (en) | 1998-05-20 | 2001-09-11 | Molecular Machines, Inc. | Methods for detecting and identifying single molecules |
| DK1077722T3 (da) | 1998-05-22 | 2006-11-27 | Ottawa Health Research Inst | Fremgangsmåder og produkter til induktion af mukosaimmunitet |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| CA2248592A1 (en) | 1998-08-31 | 2000-02-29 | Christopher D. Batich | Microspheres for use in the treatment of cancer |
| FR2783170B1 (fr) | 1998-09-11 | 2004-07-16 | Pasteur Merieux Serums Vacc | Emulsion immunostimulante |
| US6228642B1 (en) | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
| US6194328B1 (en) | 1998-12-09 | 2001-02-27 | Advanced Micro Devices, Inc. | H2 diffusion barrier formation by nitrogen incorporation in oxide layer |
| KR20010089764A (ko) | 1999-01-11 | 2001-10-08 | 둘락 노먼 씨. | 인터류킨-17과 관련된 포유류의 사이토카인, 이를코딩하는 폴리뉴클레오티드 및 이의 용도 |
| EP1053751A1 (en) | 1999-05-17 | 2000-11-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions and methods for treating cell proliferation disorders |
| US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
| ATE502117T1 (de) | 1999-06-25 | 2011-04-15 | Nanosphere Inc | Nanopartikel mit gebundenen oligonukleotiden und deren verwendungen |
| EP1210092B1 (en) | 1999-07-08 | 2009-04-08 | CAP Biotechnology, Inc. | Calcium-containing structures and methods of making and using the same |
| DE19935756A1 (de) | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation |
| US7479285B1 (en) | 1999-08-19 | 2009-01-20 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| WO2001022972A2 (en) | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
| US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| IL148844A0 (en) | 1999-09-27 | 2002-09-12 | Coley Pharm Group Inc | Methods related to immunostimulatory nucleic acid-induced interferon |
| US6585947B1 (en) | 1999-10-22 | 2003-07-01 | The Board Of Trustess Of The University Of Illinois | Method for producing silicon nanoparticles |
| US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
| EP1238071B1 (en) | 1999-11-29 | 2008-04-23 | Avi Biopharma, Inc. | Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s rrnas and their uses |
| US20030181412A1 (en) | 1999-12-21 | 2003-09-25 | Ingeneus Corporation | Method for modifying transcription and/or translation in an organism for therapeutic, prophylactic and/or analytic uses |
| IL150476A0 (en) | 1999-12-30 | 2002-12-01 | Aventis Pharma Sa | Compositions comprising nucleic acids incorporated in bilaminar mineral particles |
| CA2396113C (en) | 2000-01-13 | 2009-04-07 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
| AT409085B (de) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US20020156033A1 (en) | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
| US20040131628A1 (en) | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
| US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
| US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| JP2004515208A (ja) | 2000-03-28 | 2004-05-27 | ナノスフェアー インコーポレイテッド | オリゴヌクレオチドを付着させたナノ粒子とその使用方法 |
| CA2404041A1 (en) | 2000-03-28 | 2001-10-04 | The Regents Of The University Of California | Methods for increasing a cytotoxic t lymphocyte response in vivo |
| EP2292632A3 (en) | 2000-09-26 | 2012-07-25 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| CN1474831A (zh) | 2000-11-20 | 2004-02-11 | ����ŵ˹������ѧ�йܻ� | 膜支架蛋白 |
| US7083958B2 (en) | 2000-11-20 | 2006-08-01 | The Board Of Trustees Of The University Of Illinois | Membrane scaffold proteins |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| WO2002069369A2 (en) | 2000-12-08 | 2002-09-06 | Coley Pharmaceutical Gmbh | Cpg-like nucleic acids and methods of use thereof |
| DE10065475A1 (de) | 2000-12-28 | 2002-07-18 | Switch Biotech Ag | Verwendung von "intermediate-conductance" Kaliumkanälen und Modulatoren zur Diagnose und Behandlung von Krankheiten mit gestörter Keratinozytenfunktion |
| US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
| US7176296B2 (en) | 2001-04-30 | 2007-02-13 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| GB0111279D0 (en) | 2001-05-10 | 2001-06-27 | Nycomed Imaging As | Radiolabelled liposomes |
| US20060019917A1 (en) | 2001-05-18 | 2006-01-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA) |
| AU2002239726A1 (en) | 2001-05-25 | 2002-12-09 | Northwestern University | Non-alloying core shell nanoparticles |
| KR100904954B1 (ko) | 2001-05-30 | 2009-06-26 | 더 스크립스 리서치 인스티튜트 | 핵산용 전달 시스템 |
| KR100985457B1 (ko) | 2001-06-21 | 2010-10-06 | 다이나박스 테크놀로지 코퍼레이션 | 키메라 면역조절 화합물 및 그것들의 사용 방법 |
| JP2005511761A (ja) | 2001-07-10 | 2005-04-28 | ノース・キャロライナ・ステイト・ユニヴァーシティ | ナノ粒子送達ビヒクル |
| US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
| AU2002326561B2 (en) | 2001-08-07 | 2008-04-03 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
| EP1450856B1 (en) | 2001-09-14 | 2009-11-11 | Cytos Biotechnology AG | Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use |
| US20030134810A1 (en) | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| TW200303759A (en) | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| EP1478656B1 (en) | 2002-02-01 | 2009-09-16 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
| US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
| NZ535952A (en) | 2002-04-04 | 2009-01-31 | Coley Pharm Gmbh | Immunostimulatory G,U-containing oligoribonucleotides |
| US20040038303A1 (en) | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
| US7528116B2 (en) | 2002-05-30 | 2009-05-05 | Memorial Sloan Kettering Cancer Center | Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis |
| CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
| US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7884083B2 (en) | 2002-08-12 | 2011-02-08 | Dynavax Technologies Corporation | Immunomodulatory compositions, methods of making, and methods of use thereof |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| NZ540098A (en) | 2002-10-29 | 2008-09-26 | Coley Pharmaceutical Group Ltd | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
| GB0227738D0 (en) | 2002-11-28 | 2003-01-08 | Univ Liverpool | Nanoparticle conjugates and method of production thereof |
| DK1992635T3 (da) | 2002-12-23 | 2012-03-05 | Dynavax Tech Corp | Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| US7387271B2 (en) | 2002-12-30 | 2008-06-17 | 3M Innovative Properties Company | Immunostimulatory combinations |
| US20060105343A1 (en) | 2003-01-09 | 2006-05-18 | Children's Medical Center Corporation | Methods for diagnosis and prognosis of cancer |
| JP4726630B2 (ja) | 2003-01-16 | 2011-07-20 | イデラ ファーマシューティカルズ インコーポレイテッド | 修飾された免疫賦活性ジヌクレオチドを用いることによるオリゴヌクレオチドに基づく化合物の免疫賦活特性の調節 |
| US7354907B2 (en) | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
| JP2004315433A (ja) | 2003-04-16 | 2004-11-11 | Woong-Shick Ahn | 乳頭腫ウィルス抗原蛋白質及びＣｐＧ−オリゴデオキシヌクレオチドを含む乳頭腫ウィルス誘発疾患の予防又は治療用薬剤学的組成物 |
| KR20060012622A (ko) | 2003-05-16 | 2006-02-08 | 하이브리돈, 인코포레이티드 | 화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법 |
| US7727969B2 (en) | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| JP4874801B2 (ja) | 2003-06-11 | 2012-02-15 | イデラ ファーマシューティカルズ インコーポレイテッド | 安定化免疫調節オリゴヌクレオチド |
| US20050096263A1 (en) | 2003-10-30 | 2005-05-05 | Keay Susan K. | Novel antiproliferative factor and methods of use |
| AU2004255470B2 (en) | 2003-07-10 | 2010-08-19 | Cytos Biotechnology Ag | Packaged virus-like particles |
| MXPA06000619A (es) | 2003-07-15 | 2006-04-11 | Hybridon Inc | Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion. |
| US20080057128A1 (en) | 2003-07-18 | 2008-03-06 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from |
| DK3342425T3 (da) | 2003-09-09 | 2020-03-16 | Geron Corp | Modificerede oligonukleotider til inhibering af telomerase |
| JP4989225B2 (ja) | 2003-09-25 | 2012-08-01 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 核酸親油性接合体 |
| US6979738B2 (en) | 2003-10-22 | 2005-12-27 | Academia Sinica | Quadruplex stabilizer |
| NZ546275A (en) | 2003-10-30 | 2009-05-31 | Coley Pharm Gmbh | C-class oligonucleotides analogs with enhanced immunostimulatory potency |
| KR101138131B1 (ko) | 2003-12-08 | 2012-04-23 | 이데라 파마슈티칼즈, 인코포레이티드 | 작은 올리고뉴클레오티드-기초 화합물에 의한 면역자극특성의 조절 |
| US7846412B2 (en) | 2003-12-22 | 2010-12-07 | Emory University | Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof |
| EP1547581A1 (en) | 2003-12-23 | 2005-06-29 | Vectron Therapeutics AG | Liposomal vaccine for the treatment of human hematological malignancies |
| EP1550458A1 (en) * | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
| EP1716234B1 (de) | 2004-02-20 | 2013-10-02 | Mologen AG | Substituiertes, nicht-kodierendes nukleinsäuremolekül zur therapeutischen und prophylaktischen immunstimulation in menschen und höheren tieren |
| WO2005082922A1 (en) | 2004-02-26 | 2005-09-09 | Layerlab Aktiebolag | Oligonucleotides related to lipid membrane attachments |
| JP2007531746A (ja) | 2004-04-02 | 2007-11-08 | コーリー ファーマシューティカル グループ，インコーポレイテッド | Ｉｌ−１０応答を誘導するための免疫活性化核酸 |
| WO2005108614A2 (en) | 2004-04-07 | 2005-11-17 | Northwestern University | Reversible and chemically programmable micelle assembly with dna block-copolymer amphiphiles |
| GB0409940D0 (en) | 2004-05-04 | 2004-06-09 | Glaxosmithkline Biolog Sa | Vaccine |
| GB0411537D0 (en) | 2004-05-24 | 2004-06-23 | Midatech Ltd | Nanoparticles comprising rna ligands |
| EP1756289B1 (en) | 2004-05-24 | 2015-01-14 | Midatech Ltd. | Nanoparticles comprising rna ligands |
| US7964196B2 (en) | 2004-05-25 | 2011-06-21 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| WO2006080946A2 (en) | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
| EP1604669A1 (en) | 2004-06-10 | 2005-12-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of ATP analogues for treatment of cardiovascular diseases |
| US7498425B2 (en) | 2004-06-15 | 2009-03-03 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
| BRPI0512110A (pt) | 2004-06-15 | 2007-10-23 | Idera Pharmaceutical Inc | multìmeros de oligonucleotìdeos imunoestimulatórios |
| WO2006014653A1 (en) | 2004-07-20 | 2006-02-09 | Schering Corporation | Induction of apoptosis in toll-like receptor expressing tumor cells |
| WO2006012695A1 (en) | 2004-08-04 | 2006-02-09 | Panvax Limited | An immunogenic composition |
| WO2006015560A1 (de) | 2004-08-09 | 2006-02-16 | Mologen Ag | Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen |
| WO2006044660A2 (en) | 2004-10-14 | 2006-04-27 | Vanderbilt University | Functionalized solid lipid nanoparticles and methods of making and using same |
| MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| KR100721928B1 (ko) | 2004-11-05 | 2007-05-28 | 주식회사 바이오씨에스 | ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물 |
| AU2005304771A1 (en) | 2004-11-09 | 2006-05-18 | University Of Southern California | Targeted innate immunity |
| JP2008521385A (ja) | 2004-11-29 | 2008-06-26 | 長春華普生物技術有限公司 | アジュバントとしてのＣｐＧ含有一本鎖デオキシヌクレオチド |
| CN101218254A (zh) | 2005-02-14 | 2008-07-09 | 惠氏公司 | 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途 |
| CA2597724A1 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| KR20070110901A (ko) | 2005-03-04 | 2007-11-20 | 다이나박스 테크놀로지 코퍼레이션 | 항원에 콘쥬게이트되고 버퍼 조건 및 추가의 부형제들에의해 안정화된 면역자극성 서열(ｉｓｓ)을 갖는올리고뉴클레오티드를 포함하는 백신 |
| JP2008533157A (ja) | 2005-03-14 | 2008-08-21 | マサチューセッツ・インスティテュート・オブ・テクノロジー | 疾患および障害の診断および処置のためのナノセル |
| JP2008538280A (ja) | 2005-03-29 | 2008-10-23 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | 脂質二分子膜の製造方法 |
| DE102005016873A1 (de) | 2005-04-12 | 2006-10-19 | Magforce Nanotechnologies Ag | Nanopartikel-Wirstoff-Konjugate |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| WO2006124089A1 (en) | 2005-05-12 | 2006-11-23 | The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Self-assembled nucleic acid nanoarrays and uses therefor |
| EP2669269B1 (en) | 2005-05-27 | 2019-05-22 | The University of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
| WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| WO2007008463A2 (en) | 2005-07-07 | 2007-01-18 | Coley Pharmaceutical Group, Inc. | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| EP1929014B1 (en) | 2005-08-31 | 2014-08-13 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Methods of altering an immune response induced by d-type cpg oligodeoxynucleotides |
| US20090221095A1 (en) | 2005-10-13 | 2009-09-03 | Northwestern University | Colorimetric Screening of DNA Binding/Intercalating Agents with Gold Nanoparticle Probes |
| US20070093439A1 (en) | 2005-10-25 | 2007-04-26 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
| FR2892819B1 (fr) | 2005-10-28 | 2008-02-01 | Centre Nat Rech Scient | Nanoparticules a luminescence persistance pour leur utilisation en tant qu'agent de diagnostic destine a l'imagerie optique in vivo |
| US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| EP1942945B1 (en) | 2005-11-07 | 2011-10-19 | Idera Pharmaceuticals | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| MX2008006004A (es) | 2005-11-07 | 2008-10-01 | Idera Pharmaceuticals Inc | Propiedades inmunoestimuladoras de compuestos a base de oligonucleotidos que comprenden dinucleotidos inmunoestimuladores modificados. |
| US7776834B2 (en) | 2005-11-07 | 2010-08-17 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| NZ569086A (en) | 2005-12-01 | 2011-07-29 | Trinity College Dublin | Compositions comprising a Toll-like receptor (TLR) agonist and an immune modulator for treating Th1-mediated conditions, such as cancer and infectious diseases |
| JP5122474B2 (ja) | 2005-12-01 | 2013-01-16 | プロネイ・セラピューティクス・インコーポレイテッド | 両性リポソーム製剤 |
| US20090317802A1 (en) | 2005-12-09 | 2009-12-24 | Bhatia Sangeeta N | Compositions and Methods to Monitor RNA Delivery to Cells |
| AU2006325225B2 (en) | 2005-12-14 | 2013-07-04 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| JP2009520502A (ja) | 2005-12-20 | 2009-05-28 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｃｇジヌクレオチド修飾物を含有するトール様受容体の新規な合成アゴニスト |
| EP1962909A4 (en) | 2005-12-20 | 2012-04-18 | Idera Pharmaceuticals Inc | IMMUNOSTIMULATING ACTIVITY OF PALINDROMIC IMMUNOMODULATORY OLIGONUCLEOTIDES (IMO TM) CONTAINING DIFFERENT LENGTHS OF PALINDROMIC SEGMENTS |
| US20070148251A1 (en) | 2005-12-22 | 2007-06-28 | Hossainy Syed F A | Nanoparticle releasing medical devices |
| US20070243132A1 (en) | 2005-12-22 | 2007-10-18 | Apollo Life Sciences Limited | Transdermal delivery of pharmaceutical agents |
| WO2007120368A2 (en) | 2006-01-09 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
| AU2007212700A1 (en) | 2006-01-26 | 2007-08-16 | University Of Massachusetts | RNA interference agents for therapeutic use |
| US7723045B2 (en) | 2006-02-10 | 2010-05-25 | The Regents Of The University Of California | Assays to predict atherosclerosis and dysfunctional high-density lipoprotein |
| WO2007095316A2 (en) | 2006-02-15 | 2007-08-23 | Coley Pharmaceutical Gmbh | Compositions and methods for oligonucleotide formulations |
| EP1820804A1 (en) | 2006-02-20 | 2007-08-22 | Humboldt-Universität zu Berlin | Lipidated oligonucleotides |
| US8361494B2 (en) | 2006-03-10 | 2013-01-29 | The Trustees Of The University Of Pennsylvania | Biomimetic iron-oxide-containing lipoprotein and related materials |
| EP2012772A1 (en) | 2006-04-26 | 2009-01-14 | The Uab Research Foundation | Reducing cancer cell invasion using an inhibitor of toll like receptor signaling |
| CN101490257A (zh) | 2006-05-11 | 2009-07-22 | 莫洛根股份公司 | 用于免疫刺激的多聚体 |
| WO2007137117A2 (en) | 2006-05-17 | 2007-11-29 | Massachusetts Institute Of Technology | Aptamer-directed drug delivery |
| US20090280188A1 (en) | 2006-06-23 | 2009-11-12 | Northwestern University | Asymmetric functionalizated nanoparticles and methods of use |
| US8017237B2 (en) | 2006-06-23 | 2011-09-13 | Abbott Cardiovascular Systems, Inc. | Nanoshells on polymers |
| JP2010507361A (ja) * | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸 |
| US20080124366A1 (en) | 2006-08-06 | 2008-05-29 | Ohlfest John R | Methods and Compositions for Treating Tumors |
| CA2664919A1 (en) | 2006-08-08 | 2008-02-21 | Board Of Regents Of The University Of Texas | Multistage delivery of active agents |
| EP2468300B1 (en) | 2006-09-26 | 2017-12-20 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US20100099858A1 (en) | 2006-09-28 | 2010-04-22 | Mirkin Chad A | Maximizing Oligonucleotide Loading on Gold Nanoparticle |
| EP1914234A1 (en) | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| US7976743B2 (en) | 2006-10-16 | 2011-07-12 | Northwestern University | Gas-containing liposomes |
| EP2079305A4 (en) | 2006-12-12 | 2010-01-27 | Idera Pharmaceuticals Inc | SYNTHETIC AGONISTS OF TLR9 |
| US20080181928A1 (en) | 2006-12-22 | 2008-07-31 | Miv Therapeutics, Inc. | Coatings for implantable medical devices for liposome delivery |
| US8415461B2 (en) | 2007-01-19 | 2013-04-09 | The Board Of Trustees Of The University Of Illinois | Amphiphilic substances and functionalized lipid vesicles including the same |
| EP2111218B1 (en) | 2007-01-24 | 2014-07-02 | Syddansk Universitet | Dna controlled assembly of lipid membranes |
| AU2008212820B2 (en) | 2007-02-09 | 2014-01-30 | Northwestern University | Particles for detecting intracellular targets |
| CA2679586A1 (en) | 2007-02-27 | 2008-10-23 | Northwestern University | Molecule attachment to nanoparticles |
| AR065865A1 (es) | 2007-03-30 | 2009-07-08 | Hirofumi Takeuchi | Liposoma para la administracion pulmonar para controlar el suministro de la droga |
| US20090074828A1 (en) | 2007-04-04 | 2009-03-19 | Massachusetts Institute Of Technology | Poly(amino acid) targeting moieties |
| JP5479319B2 (ja) | 2007-04-12 | 2014-04-23 | バイオメット・バイオロジックス・リミテッド・ライアビリティ・カンパニー | ブイ式懸濁液分画システム |
| SI2170353T1 (sl) | 2007-05-18 | 2015-09-30 | Adiu Tide Pharmaceuticals Gmbh | Fosfatno modificirani oligonukleotidni analogi z imunostimulatorno aktivnostjo |
| EP2826863B1 (en) | 2007-05-30 | 2017-08-23 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| WO2008151022A2 (en) | 2007-05-31 | 2008-12-11 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
| WO2008148862A1 (en) | 2007-06-05 | 2008-12-11 | Melica Hb | Methods and materials related to hair pigmentation and cancer |
| KR101343489B1 (ko) | 2007-07-09 | 2013-12-20 | 이데라 파마슈티칼즈, 인코포레이티드 | 안정화된 면역 조절성 ｒｎａ（ｓｉｍｒａ）화합물 |
| US20100272813A1 (en) | 2007-07-23 | 2010-10-28 | Aarhus Universitet | Nanoparticle-mediated treatment for inflammatory diseases |
| CA2693266C (en) | 2007-08-01 | 2015-06-30 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
| KR20100045508A (ko) | 2007-08-13 | 2010-05-03 | 콜리 파마슈티칼 게엠베하 | 특이적 면역 조절 프로필을 유도하는 규정된 뉴클레오티드간 연결의 환경에서의 ｒｎａ 서열 모티프 |
| JP2010536787A (ja) | 2007-08-15 | 2010-12-02 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｏｌｌ様受容体モジュレータ |
| US8563527B2 (en) | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
| EP2200639B1 (en) | 2007-09-24 | 2016-03-30 | Government of the USA, as Represented by the Secretary, Department of Health and Human Services | Immunostimulatory combinations of tlr3 ligands with tlr2 and tlr9 agonists and methods of use |
| WO2009049208A1 (en) | 2007-10-12 | 2009-04-16 | The University Of North Carolina At Chapel Hill | Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents |
| CN101980712B (zh) | 2007-10-29 | 2015-02-18 | 雷古拉斯治疗公司 | 用于肝癌治疗的靶向微小rna |
| EP2058397A1 (de) | 2007-11-07 | 2009-05-13 | Mologen AG | Multimeres Assemblat zur Immunstimulation |
| CN101970687A (zh) | 2007-11-09 | 2011-02-09 | 东北大学 | 用于体内基因输送的自组装胶束样纳米颗粒 |
| US20090148384A1 (en) | 2007-12-10 | 2009-06-11 | Fischer Katrin | Functionalized, solid polymer nanoparticles comprising epothilones |
| US20110020242A1 (en) | 2007-12-12 | 2011-01-27 | Gang Zheng | High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles |
| WO2009089117A1 (en) | 2008-01-04 | 2009-07-16 | Hormel Foods Corporation | Encapsulation of oxidatively unstable compounds |
| AU2009215795A1 (en) | 2008-02-21 | 2009-08-27 | University Of Kentucky Research Foundation | Ultra-small RNAs as toll-like receptor-3 antagonists |
| BRPI0910036B8 (pt) | 2008-03-25 | 2021-05-25 | Juvaris Biotherapeutics Inc | kit compreendendo um primeiro administrador para via intra-venosa de um complexo de lipídio catiônico-dna (cldc) e um segundo administrador de uma vacina |
| EP2105145A1 (en) | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
| WO2009131931A1 (en) | 2008-04-21 | 2009-10-29 | 3M Innovative Properties Company | Nitric oxide-releasing compositions, devices and methods |
| JP5539962B2 (ja) | 2008-04-25 | 2014-07-02 | ノースウェスタン、ユニバーシティ | コレステロールを隔離するのに適したナノ構造体 |
| EP2288381A2 (en) | 2008-05-02 | 2011-03-02 | Cancer Research Technology Limited | Products and methods for stimulating an immune response |
| US8063131B2 (en) | 2008-06-18 | 2011-11-22 | University Of Washington | Nanoparticle-amphipol complexes for nucleic acid intracellular delivery and imaging |
| US8268796B2 (en) | 2008-06-27 | 2012-09-18 | Children's Hospital & Research Center At Oakland | Lipophilic nucleic acid delivery vehicle and methods of use thereof |
| EP2318425A2 (en) | 2008-07-28 | 2011-05-11 | Idera Pharmaceuticals, Inc. | Modulation of toll-like receptor 9 expression by antisense oligonucleotides |
| JP2011529704A (ja) | 2008-08-04 | 2011-12-15 | イデラ ファーマシューティカルズ インコーポレイテッド | アンチセンスオリゴヌクレオチドによるＴｏｌｌ様受容体３発現の調節 |
| US20100047188A1 (en) | 2008-08-04 | 2010-02-25 | Idera Pharmaceuticals, Inc. | Modulation of toll-like receptor 8 expression by antisense oligonucleotides |
| US20100092486A1 (en) | 2008-08-08 | 2010-04-15 | Idera Pharmaceuticals, Inc. | Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides |
| WO2010023216A1 (en) | 2008-08-28 | 2010-03-04 | Glaxosmithkline Biologicals S.A. | Vaccine |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| US9061001B2 (en) | 2008-10-16 | 2015-06-23 | University Of Saskatchewan | Combination adjuvant formulation |
| US8574582B2 (en) | 2008-10-31 | 2013-11-05 | Janssen Biotech, Inc. | Methods for mediating fibrotic response |
| US20130090457A1 (en) | 2008-10-31 | 2013-04-11 | Janssen Biotech, Inc. | Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases |
| US20110223257A1 (en) | 2008-11-17 | 2011-09-15 | Enzon Pharmaceuticals, Inc. | Releasable fusogenic lipids for nucleic acids delivery systems |
| AU2009316286B2 (en) | 2008-11-24 | 2016-05-26 | Northwestern University | Polyvalent RNA-nanoparticle compositions |
| US20120093914A1 (en) * | 2008-11-24 | 2012-04-19 | Moma Therapeutics | Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration |
| KR101329374B1 (ko) | 2008-12-09 | 2013-11-14 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 면역자극성 올리고뉴클레오타이드 |
| WO2010078516A2 (en) | 2009-01-01 | 2010-07-08 | Cornell University | Multifunctional nucleic acid nano-structures |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| AU2010203474B2 (en) | 2009-01-08 | 2015-11-19 | Northwestern University | Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates |
| WO2010085959A1 (en) | 2009-01-28 | 2010-08-05 | Aarhus Universitet | Treatment of radiation-induced fibrosis |
| JP2012516352A (ja) | 2009-01-30 | 2012-07-19 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９の合成アゴニスト |
| WO2010091293A1 (en) | 2009-02-06 | 2010-08-12 | The Regents Of The University Of California | Plasmonic system for detecting binding of biological molecules |
| AR070368A2 (es) | 2009-02-12 | 2010-03-31 | Smithkline Beecham Biolog | Procedimiento para la preparacion de una composicion de vacuna que comprende un inmunoestimulante un antigeno y una sal metalica y uso de dicha composicion para preparar un medicamento.composicion de vacuna |
| CA2754043A1 (en) | 2009-03-12 | 2010-09-16 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
| CA2755245A1 (en) | 2009-03-13 | 2010-09-16 | Egen, Inc. | Compositions and methods for the delivery of biologically active rnas |
| KR20170072367A (ko) | 2009-04-15 | 2017-06-26 | 노오쓰웨스턴 유니버시티 | 올리고뉴클레오티드 관능화된 나노입자의 전달 |
| EP2246433A1 (de) | 2009-04-30 | 2010-11-03 | Mologen AG | Concatemere zur Immunmodulation |
| KR101360432B1 (ko) | 2009-06-18 | 2014-02-25 | 한림대학교 산학협력단 | 리포좀에 포집된 올리고뉴클레오타이드를 유효성분으로 하는 면역증강 조성물 |
| EP2453903B1 (en) | 2009-07-17 | 2016-08-17 | Industry Academic Cooperation Foundation, Hallym University | Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes |
| WO2011017382A2 (en) * | 2009-08-03 | 2011-02-10 | The Regents Of The University Of California | Nanofibers and morphology shifting micelles |
| US20120277283A1 (en) | 2009-08-04 | 2012-11-01 | Mirkin Chad A | Localized Delivery of Gold Nanoparticles for Therapeutic and Diagnostic Applications |
| WO2011017690A2 (en) | 2009-08-07 | 2011-02-10 | Northwestern University | Intracellular delivery of contrast agents with functionalized nanoparticles |
| HUE026020T2 (en) | 2009-08-27 | 2016-05-30 | Idera Pharmaceuticals Inc | Preparation for inhibiting gene expression and its uses |
| CN102625697A (zh) | 2009-09-01 | 2012-08-01 | 西北大学 | 使用经寡核苷酸修饰的纳米颗粒作为载体来递送治疗剂 |
| WO2011028847A1 (en) | 2009-09-01 | 2011-03-10 | Northwestern University | Polyvalent polynucleotide nanoparticle conjugates as delivery vehicles for a chemotherapeutic agent |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| WO2011044545A2 (en) | 2009-10-09 | 2011-04-14 | Sigalov Alexander B | Methods and compositions for targeted imaging |
| KR101132626B1 (ko) | 2009-10-12 | 2012-04-02 | 주식회사 녹십자 | 난용성 약물의 전달을 위한 고밀도지단백 나노입자의 제조방법 |
| US20110111974A1 (en) | 2009-10-23 | 2011-05-12 | Northwestern University | Short Duplex Probes for Enhanced Target Hybridization |
| CN102666879B (zh) | 2009-10-30 | 2016-02-24 | 西北大学 | 模板化的纳米缀合物 |
| SI2506857T1 (en) | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases |
| WO2011072133A1 (en) | 2009-12-09 | 2011-06-16 | William Marsh Rice University | Therapeutic compositions and methods for delivery of active agents cleavably linked to nanoparticles |
| JP2013515697A (ja) | 2009-12-23 | 2013-05-09 | マックスプランク−ゲセルシャフト・ツール・フェーデルング・デル・ヴィッセンシャフテン・エー・ファウ | インフルエンザ標的 |
| US20130178610A1 (en) | 2009-12-24 | 2013-07-11 | Chad A. Mirkin | Oligonucleotide specific uptake of nanoconjugates |
| EP2525780B1 (en) | 2010-01-19 | 2022-09-07 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
| EP2399608B1 (en) | 2010-03-05 | 2020-07-08 | Sebastian Fuchs | Immunomodulating nanoparticulate composition for use in inhalation therapy |
| US20130101512A1 (en) | 2010-03-12 | 2013-04-25 | Chad A. Mirkin | Crosslinked polynucleotide structure |
| SG184127A1 (en) | 2010-03-19 | 2012-10-30 | Massachusetts Inst Technology | Lipid vesicle compositions and methods of use |
| JP2013525285A (ja) | 2010-04-08 | 2013-06-20 | サンフォード−バーナム メディカル リサーチ インスティテュート | 化合物の送達を増強するための方法および組成物 |
| CA2798074A1 (en) | 2010-04-27 | 2011-11-03 | The Johns Hopkins University | Immunogenic compositions and methods for treating neoplasia |
| EP3023496B1 (en) | 2010-05-13 | 2020-07-29 | Sarepta Therapeutics, Inc. | Compounds which modulate interleukins 17 and 23 signaling activity |
| KR101198715B1 (ko) | 2010-05-14 | 2012-11-13 | 한국생명공학연구원 | 핵산 및 친수성 음이온 화합물의 고효율 포획을 위한 비대칭 리포솜 및 이의 제조방법 |
| CN107029223A (zh) | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
| HRP20181039T1 (hr) | 2010-05-28 | 2018-08-24 | Zoetis Belgium S.A. | Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans |
| WO2011156895A2 (en) | 2010-06-14 | 2011-12-22 | National Research Council Of Canada | Magnetic nanoparticles and uses thereof |
| CN103153346A (zh) | 2010-06-16 | 2013-06-12 | 戴纳瓦克斯技术公司 | 使用tlr7和/或tlr9抑制剂的治疗方法 |
| WO2012006634A2 (en) | 2010-07-09 | 2012-01-12 | The Board Of Trustees Of The University Of Illiniois | Prostate specific antigen (psa) peptide therapy |
| EP3269811B1 (en) | 2010-07-28 | 2020-10-07 | Advanced Innovation Development Co. Ltd. | Nucleic acid having adjuvant activity and use thereof |
| EP2449113B8 (en) | 2010-07-30 | 2015-11-25 | CureVac AG | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| GB201014026D0 (en) | 2010-08-20 | 2010-10-06 | Ucl Business Plc | Treatment |
| WO2012031205A2 (en) | 2010-09-03 | 2012-03-08 | The Brigham And Women's Hospital, Inc. | Lipid-polymer hybrid particles |
| JP5927194B2 (ja) | 2010-09-24 | 2016-06-01 | マリンクロッド エルエルシー | 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート |
| US20130095039A1 (en) | 2010-09-30 | 2013-04-18 | The Board Of Trustees Of The University Of Illinois | Nucleic acid-mediated shape control of nanoparticles |
| EP2632434B1 (en) | 2010-10-26 | 2025-08-20 | AC Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| CN107012149A (zh) | 2010-11-19 | 2017-08-04 | 艾德拉药物股份有限公司 | 调控基于toll‑样受体的免疫应答的免疫调节寡核苷酸(iro)化合物 |
| WO2012084991A1 (en) | 2010-12-21 | 2012-06-28 | Index Pharmaceuticals Ab | Biologically active oligonucleotides capable of modulating the immune system ii |
| GB201021867D0 (en) | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
| GB201021873D0 (en) | 2010-12-23 | 2011-02-02 | Mologen Ag | DNA expression construct |
| US9999673B2 (en) | 2011-01-11 | 2018-06-19 | Alnylam Pharmaceuticals, Inc. | PEGylated lipids and their use for drug delivery |
| DK2663555T3 (en) | 2011-01-12 | 2017-03-27 | Ventirx Pharmaceuticals Inc | SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS |
| US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
| AU2012250050B2 (en) | 2011-04-28 | 2017-04-06 | Platform Brightworks Two, Ltd. | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
| EP3494974B1 (en) * | 2011-07-08 | 2023-10-18 | The University of North Carolina at Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
| US9517277B2 (en) | 2011-07-15 | 2016-12-13 | University Of Georgia Research Foundation, Inc. | Immune-stimulating photoactive hybrid nanoparticles |
| EP2548571A1 (en) | 2011-07-22 | 2013-01-23 | Institut Curie | Compositions having means for targeting at least one antigen to dendritic cells |
| JP2014521687A (ja) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア |
| US9901616B2 (en) | 2011-08-31 | 2018-02-27 | University Of Georgia Research Foundation, Inc. | Apoptosis-targeting nanoparticles |
| CN104024854A (zh) | 2011-09-11 | 2014-09-03 | 奥拉森斯有限责任公司 | 细胞摄取对照系统 |
| CN104023749B (zh) | 2011-09-14 | 2019-12-17 | 西北大学 | 能穿过血脑屏障的纳米缀合物 |
| HK1200484A1 (zh) | 2011-09-14 | 2015-08-07 | Translate Bio Ma, Inc. | 多聚寡核苷酸化合物 |
| WO2013043647A1 (en) | 2011-09-19 | 2013-03-28 | The Johns Hopkins University | Cancer immunotherapy |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| IN2014CN02581A (enExample) | 2011-10-06 | 2015-08-07 | Immunovaccine Technologies Inc | |
| WO2013098813A1 (en) | 2012-01-01 | 2013-07-04 | Qbi Enterprises Ltd. | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| JP6375289B2 (ja) | 2012-04-05 | 2018-08-15 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫刺激組成物およびその使用方法 |
| PL2844282T3 (pl) | 2012-05-04 | 2019-11-29 | Pfizer | Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce |
| WO2013173307A1 (en) | 2012-05-16 | 2013-11-21 | Neil Desai | Multi-target modulation for treating fibrosis and inflammatory conditions |
| CA2874490C (en) | 2012-05-23 | 2021-11-16 | The Ohio State University | Tertiary quaternary amine-based cationic lipid nanoparticle compositions and methods of making and methods of using the same |
| SG11201500243WA (en) | 2012-07-13 | 2015-04-29 | Shin Nippon Biomedical Lab Ltd | Chiral nucleic acid adjuvant |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| US9931418B2 (en) | 2012-08-07 | 2018-04-03 | Northeastern University | Compositions for the delivery of RNA and drugs into cells |
| US9095625B2 (en) | 2012-08-31 | 2015-08-04 | University Of Massachusetts | Graft-copolymer stabilized metal nanoparticles |
| US9868955B2 (en) | 2012-09-29 | 2018-01-16 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
| ES2873600T3 (es) | 2013-02-05 | 2021-11-03 | 1Globe Health Inst Llc | Nanopartículas biodegradables y clínicamente compatibles como vehículos de suministro de fármacos. |
| US9968673B2 (en) | 2013-02-26 | 2018-05-15 | Commissariat á l'ènergie atomique et aux ènergies alternatives | Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent |
| CN103212089B (zh) | 2013-04-07 | 2016-08-24 | 中国科学院上海应用物理研究所 | 一种碳纳米材料-免疫刺激序列复合物的制备方法及其应用 |
| US9617544B2 (en) | 2013-04-11 | 2017-04-11 | The Board Of Trustees Of The University Of Illinois | Nanoparticle mediated delivery of siRNA |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| GB2514591A (en) | 2013-05-30 | 2014-12-03 | Mologen Ag | Predictive biomarker for cancer therapy |
| WO2014201245A1 (en) | 2013-06-12 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors |
| AU2014292928A1 (en) | 2013-07-25 | 2016-03-03 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunoregulatory agents |
| CA2919268C (en) | 2013-07-25 | 2023-09-05 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| US20150037374A1 (en) | 2013-07-31 | 2015-02-05 | Csl Limited | Anti-tumor compositions and uses thereof |
| US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
| JP2016531570A (ja) | 2013-08-16 | 2016-10-13 | ラナ セラピューティクス インコーポレイテッド | ユークロマチン領域を標的とするオリゴヌクレオチド |
| EP3049521B1 (en) | 2013-09-25 | 2019-03-06 | Cornell University | Compounds for inducing anti-tumor immunity and methods thereof |
| KR101465365B1 (ko) | 2013-10-15 | 2014-11-25 | 성균관대학교산학협력단 | 리포좀 내 고분자 충진된 다중 기능 복합 입자체 및 이의 제조방법 |
| WO2015077657A2 (en) | 2013-11-22 | 2015-05-28 | City Of Hope | Stat3 inhibitors and uses thereof |
| WO2015126502A2 (en) * | 2013-12-03 | 2015-08-27 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
| JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| WO2015108046A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| WO2015120382A1 (en) | 2014-02-07 | 2015-08-13 | The Johns Hopkins University | Predicting response to epigenetic drug therapy |
| GB2523187A (en) | 2014-02-18 | 2015-08-19 | Mologen Ag | Covalently closed non-coding immunomodulatory DNA construct |
| CA2940794C (en) | 2014-02-28 | 2022-05-31 | Bayer Animal Health Gmbh | Immunostimulatory plasmids |
| EP3113759B1 (en) | 2014-03-05 | 2021-05-12 | Orbis Health Solutions LLC | Vaccine delivery systems using yeast cell wall particles |
| EP3129391A4 (en) | 2014-04-03 | 2017-12-20 | Exicure, Inc. | Self assembling nucleic acid nanostructures |
| WO2015152693A2 (ko) | 2014-04-04 | 2015-10-08 | (주)바이오니아 | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 |
| CN107073090A (zh) | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | 结合的疫苗装置和杀死癌细胞的方法 |
| US10413565B2 (en) | 2014-04-30 | 2019-09-17 | Northwestern University | Nanostructures for modulating intercellular communication and uses thereof |
| US10278984B2 (en) | 2014-05-02 | 2019-05-07 | Nitor Therapeutics | Guanosine as an immune potentiator mediated through toll receptors |
| AU2015269412B2 (en) * | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| TW201620526A (zh) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法 |
| US9919058B2 (en) | 2014-07-15 | 2018-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Polyketal particles including a CpG oligodeoxynucleotide for the treatment of lung cancer |
| KR20170042758A (ko) | 2014-08-20 | 2017-04-19 | 노오쓰웨스턴 유니버시티 | 안티센스 유전자 조절을 위한 생체에 적합한 무한 배위 중합체 나노입자-핵산 컨쥬게이트 |
| BR112017007012A2 (pt) | 2014-10-06 | 2018-03-06 | Exicure Inc | compostos anti-tnf |
| EP3247796A4 (en) | 2015-01-14 | 2018-07-11 | Exicure, Inc. | Nucleic acid nanostructures with core motifs |
| US20180042848A1 (en) | 2015-02-18 | 2018-02-15 | Exicure, Inc. | Immuno-regulatory lipid containing spherical nucleic acids |
| US10078092B2 (en) | 2015-03-18 | 2018-09-18 | Northwestern University | Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules |
| EP3298140B1 (en) | 2015-05-19 | 2024-04-24 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
| US20180214376A1 (en) | 2015-07-14 | 2018-08-02 | Exicure, Inc. | Spherical nucleic acid (sna)-mediated delivery of lipid-complexes to cells |
| MX2018002090A (es) | 2015-08-24 | 2018-09-12 | Halo Bio Rnai Therapeutics Inc | Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos. |
| US20200297867A1 (en) | 2016-02-01 | 2020-09-24 | Exicure, Inc. | Surface functionalization of liposomes and liposomal spherical nucleic acids (snas) |
| US20170240960A1 (en) * | 2016-02-24 | 2017-08-24 | Aurasense, Llc | Spherical nucleic acids (sna) flare based fluorescence in situ hybridization |
| WO2017184427A1 (en) | 2016-04-19 | 2017-10-26 | Exicure, Inc. | Topical administration of therapeutic agents and oligonucleotide formulations |
| CA3023451A1 (en) | 2016-05-06 | 2017-11-09 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna |
| WO2017193084A1 (en) | 2016-05-06 | 2017-11-09 | Exicure, Inc. | Tlr9-targeted spherical nucleic acids having potent antitumor activity |
| WO2017193081A1 (en) | 2016-05-06 | 2017-11-09 | Exicure, Inc. | Spherical nucleic acid tlr9 agonists |
| WO2018053508A1 (en) | 2016-09-19 | 2018-03-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for inducing an immune response |
| US20200248183A1 (en) | 2017-04-03 | 2020-08-06 | Subbarao Nallagatla | Tlr9-targeted spherical nucleic acids having potent antitumor activity |
| WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
| US20210002640A1 (en) | 2018-02-28 | 2021-01-07 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors |
| WO2019168558A1 (en) | 2018-02-28 | 2019-09-06 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors |
| US20220088059A1 (en) | 2019-02-12 | 2022-03-24 | Exicure Operating Company | Combined spherical nucleic acid and checkpoint inhibitor for antitumor therapy |
| WO2020219985A1 (en) | 2019-04-26 | 2020-10-29 | Exicure, Inc. | Administration of spherical nucleic acids for ophthalmological uses |
-
2015
- 2015-06-04 AU AU2015269412A patent/AU2015269412B2/en active Active
- 2015-06-04 EP EP15753219.3A patent/EP3164113B1/en active Active
- 2015-06-04 US US15/315,538 patent/US10434064B2/en active Active
- 2015-06-04 CN CN201580038173.5A patent/CN106535876B/zh active Active
- 2015-06-04 PL PL15753219T patent/PL3164113T3/pl unknown
- 2015-06-04 CA CA2953216A patent/CA2953216C/en active Active
- 2015-06-04 EP EP19156455.8A patent/EP3508198A1/en not_active Withdrawn
- 2015-06-04 TR TR2019/08550T patent/TR201908550T4/tr unknown
- 2015-06-04 ES ES15753219T patent/ES2725948T3/es active Active
- 2015-06-04 JP JP2016570952A patent/JP6581604B2/ja active Active
- 2015-06-04 KR KR1020167037023A patent/KR102290205B1/ko active Active
- 2015-06-04 WO PCT/US2015/034226 patent/WO2015187966A1/en not_active Ceased
-
2019
- 2019-09-12 US US16/569,007 patent/US11123294B2/en active Active
-
2021
- 2021-08-18 US US17/405,068 patent/US11957788B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015187966A1 (en) | 2015-12-10 |
| ES2725948T3 (es) | 2019-09-30 |
| EP3508198A1 (en) | 2019-07-10 |
| JP2017524658A (ja) | 2017-08-31 |
| US10434064B2 (en) | 2019-10-08 |
| EP3164113A1 (en) | 2017-05-10 |
| AU2015269412A1 (en) | 2016-12-22 |
| AU2015269412B2 (en) | 2020-03-12 |
| US11123294B2 (en) | 2021-09-21 |
| US20170157048A1 (en) | 2017-06-08 |
| KR102290205B1 (ko) | 2021-08-20 |
| US11957788B2 (en) | 2024-04-16 |
| CA2953216A1 (en) | 2015-12-10 |
| US20200069587A1 (en) | 2020-03-05 |
| KR20170005499A (ko) | 2017-01-13 |
| EP3164113B1 (en) | 2019-03-27 |
| CA2953216C (en) | 2020-12-22 |
| PL3164113T3 (pl) | 2019-09-30 |
| TR201908550T4 (tr) | 2019-07-22 |
| CN106535876A (zh) | 2017-03-22 |
| US20220257512A1 (en) | 2022-08-18 |
| CN106535876B (zh) | 2020-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11957788B2 (en) | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications | |
| JP6697384B2 (ja) | 予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物 | |
| JP5737937B2 (ja) | 安定化免疫調節ｒｎａ（ｓｉｍｒａ）化合物 | |
| CN101874112B (zh) | 特别是作为免疫刺激剂/佐剂的式(I)：GlXmGn或式(II)：ClXmCn的核酸 | |
| ES2486298T3 (es) | Análogos de oligonucleótidos inmunoestimuladores que contienen azúcares modificados | |
| US20160194642A1 (en) | Spherical nucleic acid-based constructs as immunoregulatory agents | |
| US20170175121A1 (en) | Self assembling nucleic acid nanostructures | |
| US20200297867A1 (en) | Surface functionalization of liposomes and liposomal spherical nucleic acids (snas) | |
| US20050250716A1 (en) | Immunostimulatory oligodeoxynucleotides | |
| JP2012517226A (ja) | Ｔｌｒ７の合成ｒｎａベースのアゴニスト | |
| JP2022506503A (ja) | 修飾二重鎖オリゴヌクレオチド | |
| TWI468166B (zh) | 具有增強之免疫刺激活性之經磷酸鹽修飾之寡核苷酸類似物 | |
| JP2024539435A (ja) | がんの免疫療法的治療のためのｃＧＡＳ－ＳＴＩＮＧ及びＳＴＡＴ３経路変調のための球状核酸 | |
| US20180256630A1 (en) | Use of nucleic acid-polysaccharide complexes having immunopotentiating activity as anti-tumor drug | |
| WO2009108235A2 (en) | Compositions and methods for modulating immune responses to nucleic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180601 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180601 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190226 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190527 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190719 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190731 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190830 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6581604 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |